Literature DB >> 2566844

Pathogenesis of progressive multiple sclerosis.

A J Thompson, A G Kermode, D G MacManus, D P Kingsley, B E Kendall, I F Moseley, W I McDonald.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2566844     DOI： 10.1016/s0140-6736(89)92710-4

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

Review 1.  Multiple sclerosis in the elderly patient.

Authors:  Amer Awad; Olaf Stüve
Journal:  Drugs Aging       Date:  2010-04-01       Impact factor: 3.923

2.  Clinical study of primary progressive multiple sclerosis in Northern Ireland, UK.

Authors:  G V McDonnell; S A Hawkins
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-04       Impact factor: 10.154

3.  Quantification of central motor conduction deficits in multiple sclerosis patients before and after treatment of acute exacerbation by methylprednisolone.

Authors:  A M Humm; W J Z'Graggen; R Bühler; M R Magistris; K M Rösler
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-09-20       Impact factor: 10.154

4.  Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study.

Authors:  A J Thompson; A G Kermode; D G MacManus; B E Kendall; D P Kingsley; I F Moseley; W I McDonald
Journal:  BMJ       Date:  1990-03-10

5.  An immunogenetic heterogeneity in multiple sclerosis.

Authors:  J Hillert; M Grönning; H Nyland; H Link; O Olerup
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-10       Impact factor: 10.154

6.  Patient-orientated longitudinal study of multiple sclerosis in south west England (The South West Impact of Multiple Sclerosis Project, SWIMS) 1: protocol and baseline characteristics of cohort.

Authors:  John P Zajicek; Wendy M Ingram; Jane Vickery; Siobhan Creanor; Dave E Wright; Jeremy C Hobart
Journal:  BMC Neurol       Date:  2010-10-07       Impact factor: 2.474
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.